Denovo Biopharma LLC: Schizophrenia trials

The registry lists 13 Schizophrenia studies with Denovo Biopharma LLC as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 7Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With SchizophreniaCompletedNCT01606436Phase 1Results posted
• A Physical Dependence Study in SchizophreniaCompletedNCT01452919Phase 3Results posted
• A Study of Safety and Tolerability in Subjects With SchizophreniaCompletedNCT01354353Phase 1Results posted
• A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia PatientsTerminatedNCT01328093Phase 3Results posted
• A Study of LY2140023 in Patients With SchizophreniaTerminatedNCT01307800Phase 3Results posted
• A Study in Schizophrenic PatientsTerminatedNCT01125358Phase 2Results posted
• A Study of LY2140023 in Schizophrenia Patients With Prominent Negative SymptomsCompletedNCT01052103Phase 2Results posted
• A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic PatientsCompletedNCT00845026Phase 2Results posted
• A Long-Term Safety Study of Pomaglumetad Methionil in SchizophreniaTerminatedNCT01487083Phase 3
• A Long-Term, Open-Label, Study on SchizophreniaTerminatedNCT01129674Phase 2/3
• A Comparator Study of LY2140023 Versus Placebo in Schizophrenia PatientsCompletedNCT01086748Phase 2
• A Study for Participants With SchizophreniaCompletedNCT00520923Phase 2
• Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and PlaceboCompletedNCT00149292Phase 2